NEW YORK (GenomeWeb) – Singulex said today that it has signed a license and supply agreement that gives it access to the Thermo Fisher Scientific BRAHMS PCT procalcitonin immunoassay.

The firm said that it plans to combine its proprietary single molecule counting technology with the Thermo Fisher procalcitonin assay to develop a sepsis and systemic inflammatory response syndrome (SIRS) rule-out and rule-in test on its Sgx Clarity next generation immunodiagnostics platform.  

Further terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.